[HTML][HTML] Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
…, C Cordon-Cardo, JS Jhang, SA Arinsburg… - Nature medicine, 2020 - nature.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments 1 . …
coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments 1 . …
[HTML][HTML] Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
…, R Mendu, J Jhang, S Arinsburg… - The Lancet …, 2020 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic. The proportion of infected individuals who seroconvert is still an open …
global pandemic. The proportion of infected individuals who seroconvert is still an open …
Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2
…, F Amanat, I Baine, S Arinsburg… - The Journal of …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected
millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the …
millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the …
Neutralizing antibody responses in COVID-19 convalescent sera
…, AF Payne, SJ Wong, S Arinsburg… - The Journal of …, 2021 - academic.oup.com
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …
Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region
…, G Patel, A Firpo, R Mendu, J Jhang, S Arinsburg… - MedRxiv, 2020 - medrxiv.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic. The percentage of infected individuals who seroconvert is still an open …
global pandemic. The percentage of infected individuals who seroconvert is still an open …
Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera
…, GD Haas, F Amanat, J Klingler, I Baine, S Arinsburg… - MBio, 2021 - Am Soc Microbiol
The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop
vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, …
vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, …
[HTML][HTML] Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies
G Lancman, S Arinsburg, J Jhang, HJ Cho… - Frontiers in …, 2018 - frontiersin.org
Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma
(MM) and has recently been approved in the frontline setting for MM patients ineligible …
(MM) and has recently been approved in the frontline setting for MM patients ineligible …
Transfusion reactions associated with COVID‐19 convalescent plasma therapy for SARS‐CoV‐2
…, L Rudon, P Galdon, JS Jhang, SA Arinsburg… - …, 2021 - Wiley Online Library
Background Convalescent plasma (CP) for treatment of severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) has shown preliminary signs of effectiveness in moderate to …
coronavirus 2 (SARS‐CoV‐2) has shown preliminary signs of effectiveness in moderate to …
A high-throughput assay for circulating antibodies directed against the S protein of severe acute respiratory syndrome coronavirus 2
…, C Hioe, F Amanat, I Baine, S Arinsburg… - The Journal of …, 2020 - academic.oup.com
More than 24 million infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
were confirmed globally by September 2020. While polymerase chain reaction–…
were confirmed globally by September 2020. While polymerase chain reaction–…
[HTML][HTML] Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma
A Chari, S Arinsburg, S Jagannath, T Satta… - … Myeloma and Leukemia, 2018 - Elsevier
Introduction Daratumumab, a human CD38 monoclonal antibody approved for multiple
myeloma (MM) treatment, binds red blood cells (RBCs), resulting in panagglutination in …
myeloma (MM) treatment, binds red blood cells (RBCs), resulting in panagglutination in …